{"filings":[{"id":1111055,"accession_number":"0001193125-26-274135","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-06-17T20:05:17+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Outset Medical secures ~$40M HCA commitment for Tablo hemodialysis system refresh through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HCA commits to purchase new Tablo hemodialysis consoles from 2026 through 2028 under Refresh Amendment; aggregate contract value ~$40M net of rebates.","Term extended to Dec 31, 2028; existing consoles traded in for credit; HCA cannot terminate for convenience during refresh.","Outset reiterates 2026 financial guidance; expects to provide more detail on deal's 2026 impact later this year.","Amendment includes rebates, uptime guarantees, and support service fee terms; certain pricing details redacted as confidential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888211,"accession_number":"0001193125-26-259527","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-06-05T20:05:17+00:00","items":["5.07"],"status":"ready","headline":"Outset Medical annual meeting results: directors elected, say-on-pay approved, KPMG ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Brent D. Lang and Karen Prange elected as Class III directors to serve until 2029 annual meeting.","Advisory vote on named executive officer compensation approved: 7,548,774 for, 3,196,870 against, 6,411 abstain.","Ratification of KPMG as independent auditor for FY2026 approved: 13,554,287 for, 20,047 against, 316,530 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":746528,"accession_number":"0001193125-26-248237","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-05-29T20:05:16+00:00","items":["5.02"],"status":"ready","headline":"EVP R&D, Operations and Service Marc Nash to depart Outset Medical June 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc Nash resigned as EVP R&D, Operations and Service effective June 5, 2026.","Departure is to pursue other professional opportunities.","Company confirms no dispute or disagreement with Nash or management.","No replacement for Nash has been announced as of the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93114,"accession_number":"0001193125-26-211980","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q1 revenue down 6% to $27.9M; gross margin expands to 43.4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $27.9M (-6% YoY); recurring revenue $22.5M roughly flat.","Gross margin 43.4% (up from 37.2% YoY); product gross margin record 52.4%, service margin record 25.5%.","Net loss narrowed to $19.0M from $25.8M; cash $161M at quarter end.","Reiterated FY 2026 revenue guidance $125-130M (5-9% growth) and non-GAAP gross margin low-to-mid 40%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":27863000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104474,"accession_number":"0001193125-26-046588","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical reports FY2025 revenue $119.5M (+5% YoY); provides 2026 guidance $125-130M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $28.9M; full year 2025 revenue $119.5M (+5% YoY); recurring revenue $88.7M (+6%).","Gross margin expanded to 42.4% in Q4 (non-GAAP 42.9%), up ~600 bps vs Q4 2024.","Net loss narrowed to $81.7M in 2025 from $128M in 2024; cash $173M; ops cash burn $46M vs $116M.","Received FDA clearance for next-generation Tablo platform; launch expected in Q2 2026.","FY2026 guidance: revenue $125M-$130M (+5-9% YoY); non-GAAP gross margin low to mid-40%."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":119476000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104473,"accession_number":"0001193125-26-023428","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outset Medical receives FDA 510(k) clearance for next-generation Tablo dialysis system; Q2 2026 launch","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance granted for next-gen Tablo platform on January 27, 2026.","Tablo is first dialysis system to meet FDA's most rigorous cybersecurity guidance (June 2025).","Hardware, operating system, and software enhancements improve reliability and user experience.","Shipping to customers expected to begin in Q2 2026; current users eligible to upgrade.","CEO Leslie Trigg highlights milestone as reflecting commitment to innovation and patient safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104472,"accession_number":"0001193125-26-009865","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Outset Medical prelim Q4 rev $28.9M; FY2025 rev $119.5M (+5% YoY); cash $173M; appoints Prange","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$28.9M; full-year 2025 revenue $119.5M, up 5% from $113.7M in 2024.","Year-end cash (incl. restricted cash & short-term investments) $173M; net cash used in ops <$50M vs $116M in 2024.","Over 1,000 sites insource dialysis with Outset; ~1M treatments/year; cumulative >3M treatments on Tablo.","Andrea Saia resigned from board effective Jan 9, 2026; Karen Prange appointed to board and Compensation Committee.","Prange brings med device exec experience (Henry Schein, Boston Scientific, Johnson & Johnson)."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":119476000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120763,"accession_number":"0001193125-25-274193","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q3 revenue $29.4M (+3%); cuts FY 2025 revenue guidance to $115-120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.8M vs $27.9M a year ago; non-GAAP net loss $12M vs $20.2M.","Gross margin expanded to 39.4% (non-GAAP 39.9%) from 34.3% a year ago.","FY 2025 revenue guidance reduced to $115-120M from prior $122-126M.","Cash use improved to <$6M in Q3; total cash $182M at quarter end.","Operating expenses declined 19% YoY to $27.4M; path to profitability focus."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":90602000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137353,"accession_number":"0000950170-25-104054","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q2 revenue up 15% to $31.4M; raises FY2025 guidance to $122-126M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $31.4M (+15% YoY); Tablo console revenue up 25%; recurring revenue $22.5M (+11%).","Non-GAAP gross margin 38.4% (+110bps); operating expenses down 29% YoY; net loss $18.5M vs $34.5M.","Raised 2025 revenue guidance to $122-126M from $115-125M; expects <$50M cash use vs >$100M in 2024.","New enterprise agreement with large national health system; Tablo now in >900 U.S. acute/sub-acute sites.","Cash $187.4M at June 30; H1 cash burn reduced ~60% vs prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":61171000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154669,"accession_number":"0000950170-25-081009","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Outset Medical appoints Renee Gaeta as CFO; reaffirms $115M-$125M revenue guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Renee Gaeta appointed CFO effective June 3, 2025; succeeds Nabeel Ahmed who is leaving.","Gaeta receives $500K base salary, $2.48M RSU award, and $620K PSU award.","2025 guidance reaffirmed: revenue $115M-$125M, non-GAAP gross margin in high-30% range.","Stockholders approved adding 1.95M shares to 2020 Equity Incentive Plan and 255K shares to ESPP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154668,"accession_number":"0000950170-25-070964","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Outset Medical appoints Kevin O'Boyle to board, Dale Jones resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dale E. Jones stepped down from the Board effective May 14, 2025; no disagreement with company.","Kevin O'Boyle appointed as director and Audit Committee Chair, effective May 14, 2025.","O'Boyle brings over 20 years healthcare leadership; former CFO of NuVasive and Advanced Biohealing.","Patrick Hackett transitions from Audit Committee Chair; Andrea Saia moves to Compensation Committee.","D. Keith Grossman appointed Compensation Committee Chair; committee changes effective May 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154667,"accession_number":"0000950170-25-065680","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q1 revenue up 6%, gross margin expands to 37.2%, net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $29.8M (+6% YoY); recurring Tablo consumables & services $22.7M (+20% YoY).","Gross margin 37.2% (non-GAAP 37.6%), up from 29.2% in Q1 2024; product margin 48.3%.","Net loss $25.8M (-$3.66/share) vs. $39.9M (-$11.77) a year ago; operating cash use down 44%.","Reiterated FY2025 guidance: revenue $115M-$125M, non-GAAP gross margin high-30% range, cash use < $50M.","Tariff exemption confirmed under USMCA and for chronically disabled; no expected impact."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":29752000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173196,"accession_number":"0001193125-25-058953","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Outset Medical effects 1-for-15 reverse stock split effective March 20, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio of 1-for-15, effective 12:01 a.m. ET on March 20, 2025.","Common stock begins trading on split-adjusted basis under new CUSIP 690145206.","No fractional shares issued; cash-in-lieu paid based on March 19 closing price.","Stockholders approved split ratio range of 1:10 to 1:15 at special meeting March 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173195,"accession_number":"0001193125-25-056206","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outset Medical announces 1-for-15 reverse stock split effective March 20, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-15; outstanding shares to drop from ~265M to ~17M.","Effective 12:01 a.m. ET on March 20, 2025; split-adjusted trading starts at market open.","Symbol unchanged (OM); new CUSIP 690145206; authorized shares and par value unchanged.","Fractional shares will be cashed out; equity awards and exercise prices proportionately adjusted.","Stockholders approved split ratio on March 5, 2025; board set final ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173194,"accession_number":"0001193125-25-051981","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Outset Medical Series A conversion adds 210.7M shares; total common now 265.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On March 7, 2025, issued 19,432 Series A Non-Voting Convertible Preferred shares to directors, officers, and employees after stockholder approval.","On March 10, 2025, 842,753 Series A shares converted into 210,688,250 common shares, raising outstanding common to 265,493,926.","Certificate of Correction filed to fix a scrivener's error in the Series A conversion formula (numerator/denominator swap).","After conversion, 20,587 Series A preferred shares remain outstanding.","Issuance and conversion follow stockholder approval at the March 5, 2025 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173193,"accession_number":"0000950170-25-034593","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Outset Medical stockholders approve reverse stock split and preferred stock issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved reverse stock split at ratio of 1:10 to 1:15, board discretion within one year.","Approved issuance of Series A preferred stock convertible into >20% of outstanding common at below market price.","Approved issuance of Series A stock to directors, officers, and employees under Nasdaq Rule 5635(c).","All proposals passed with strong support; reverse split had 28.4M for vs 4.7M against.","Record date was Jan 22, 2025; 53.7M shares outstanding; quorum of 33.3M shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173192,"accession_number":"0001193125-25-036741","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Outset Medical receives second Nasdaq delisting notice; FY2024 revenue $113.7M, down 13%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Outset on Feb 24, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure period until Aug 25, 2025.","Stockholders to vote on reverse stock split (ratio 1:10 to 1:15) at special meeting March 5, 2025.","FY2024 total revenue $113.7M, down 12.8% from $130.4M in 2023; product revenue fell 21.7% to $81.0M.","Net loss narrowed to $128.0M ($2.46 loss per share) from $172.8M ($3.48) in 2023; cash rose to $124.0M from $68.5M.","Term loan balance increased to $197.4M from $130.1M; accumulated deficit reached $1.09B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173191,"accession_number":"0000950170-25-023167","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q4 revenue $29.5M, beats guidance; 2025 outlook $115-125M revenue, high-30% gross margin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $29.5M (+3% QoQ, -3% YoY); full-year $113.7M, beating prior guidance.","Q4 GAAP gross margin 36.5% (37.7% non-GAAP), up 11pp YoY; recurring revenue up 21% to $83.9M in 2024.","Q4 net loss $25.6M ($0.49/sh) vs $38.6M ($0.77/sh) YoY; non-GAAP loss $19.3M ($0.37/sh).","Tablo installed base ~6,000 consoles (+10% in 2024); cash $162M at yr-end, ~$210M after Jan 2025 financing.","2025 guidance: revenue $115-125M, non-GAAP gross margin high-30% range; cash burn <$50M vs $103M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":113689000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173190,"accession_number":"0001140361-25-001915","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Outset Medical amends bylaws to adopt majority-of-votes-cast standard for stockholder matters","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Amendment No. 1 to Bylaws on January 23, 2025, effective immediately.","Non-director stockholder matters now decided by affirmative vote of majority of votes cast.","Prior standard required majority of voting power of shares present or represented at meeting.","Only Section 1.7(a) of Bylaws was amended; no other changes to governance documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173189,"accession_number":"0001193125-25-003545","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["1.01","1.02","2.03","5.03","9.01"],"status":"ready","headline":"Outset Medical secures $100M term loan, issues warrants and Series A Preferred in refinancing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $100M initial term loan from Perceptive Credit Holdings; used proceeds to repay existing SLR credit facilities.","Issued warrant to Perceptive to purchase 5.625M shares of common stock at $0.80, exercisable for 7 years.","Issued 863,340 shares of Series A Non-Voting Convertible Preferred at $200/share, convertible into 250 common shares each after stockholder approval.","Series A Preferred accrues dividends at 8% annual rate, increasing 2% per year if stockholder approval not obtained within one year.","Delayed draw term loan of up to $25M available; additional warrant for 1.40625M shares at future market price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173188,"accession_number":"0001193125-25-001911","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Outset Medical secures $168.8M equity private placement and $125M debt facility, reports $113M 2024 revenue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 843,908 Series A convertible preferred shares at $200/share for ~$168.8M gross proceeds; insiders to invest additional $3.9M subject to shareholder approval.","New $125M senior secured credit facility from Perceptive Advisors: $100M initial term loan plus up to $25M delayed draw, maturity 2030, SOFR+8% with 2-year PIK component.","Proceeds used to repay in full ~$200M of existing credit facilities (maturing 2027) with SLR Investment and Gemino; expected to have ~$210M cash and $100M debt post-closing.","Preliminary unaudited Q4 2024 revenue of $29M and FY 2024 revenue of $113M, ahead of prior guidance.","Financing led by PFM Health Sciences and Perceptive Advisors; expected to close Jan 8, 2025, and fund operations through cashflow breakeven."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190218,"accession_number":"0000950170-24-122229","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q3 revenue $28.7M, net loss $0.55/share; raises FY2024 revenue guidance to ~$112M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $28.7M down 6% YoY but up 5% QoQ; product revenue $20.3M down 14% YoY.","Recurring revenue (cartridges + service) $21M, up 17% YoY; gross margin 34.3% vs 23.6% YoY.","Net loss $27.9M ($0.55/share) vs $46.2M ($0.93/share) in Q3 2023; non-GAAP net loss $20.2M ($0.39/share).","FY2024 revenue guidance raised to ~$112M from ~$110M; non-GAAP gross margin guided to mid-30% range.","Cash & investments $179.0M as of Sept 30, 2024; operating expenses down 36% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":84222000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206720,"accession_number":"0000950170-24-109993","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Outset Medical receives Nasdaq delisting notice for bid price below $1.00 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice dated Sept 23, 2024: closing bid price below $1.00 for 30 consecutive days violates Nasdaq Listing Rule 5450(a)(1).","Company has 180 calendar days, until March 24, 2025, to regain compliance by having $1.00+ closing bid price for 10 consecutive trading days.","If not compliant by deadline, may transfer to Nasdaq Capital Market and get additional 180-day period if eligible.","No immediate impact on listing; stock continues trading on Nasdaq Global Select Market during cure period.","Company states it will exercise diligent efforts but provides no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206719,"accession_number":"0000950170-24-097816","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jim Hinrichs resigns from Outset Medical board; Hackett named Audit Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Hinrichs resigned as director and Audit Committee Chair due to affiliation with Vantive, Baxter's kidney care spin-off.","Board size reduced from 8 to 7; resignation not due to any disagreement with the company.","Patrick T. Hackett appointed Audit Committee Chair; qualifies as audit committee financial expert.","Karen Drexler succeeds Hackett as Nominating and Corporate Governance Committee Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206718,"accession_number":"0000950170-24-092780","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q2 revenue $27.4M (-24% YoY); FY2024 guidance cut to ~$110M from $145-153M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue fell to $19.2M; service revenue rose 21.5% to $8.2M.","GAAP net loss $(0.66)/share; non-GAAP net loss $(0.47)/share.","Total gross margin improved to 35.7% from 21.4% YoY; non-GAAP gross margin 37.3%.","FY2024 revenue guidance revised to ~$110M (prior $145-153M); non-GAAP gross margin now low-to-mid 30%.","New console placements below expectations; company taking steps to improve execution."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":55556000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223932,"accession_number":"0000950170-24-066561","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Outset Medical shareholders re-elect three directors; say-on-pay approved by narrow margin","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors re-elected: Drexler (25.8M for, 7.6M withheld), Jones (32.6M for, 0.8M withheld), Trigg (32.1M for, 1.3M withheld). Broker non-votes: 5.1M.","Advisory say-on-pay proposal approved with 16.8M for, 16.5M against, 0.1M abstain; broker non-votes 5.1M. Passed by narrow margin of 370,308 votes.","Ratification of KPMG as independent auditor for fiscal 2024 approved with 38.3M for, 0.1M against, 0.1M abstain; no broker non-votes.","Annual meeting held on May 29, 2024; quorum of 38.5M shares present out of 51.7M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223931,"accession_number":"0000950170-24-055657","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Outset Medical Q1 revenue $28.2M, net loss $(0.78)/share; CTO departs, $3.0M restructuring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $28.2M, down 16% YoY; service revenue up 36% to $7.7M, recurring revenue up 24%.","GAAP net loss $(39.9)M ($(0.78)/share); non-GAAP net loss $(29.3)M ($(0.57)/share).","Total gross margin improved to 29.2% from 19.2% YoY; product margin 38.4% from 25.1%.","FY 2024 guidance reaffirmed: revenue $145-153M, non-GAAP gross margin low-30% range.","CTO Jean-Olivier Racine departs May 17; workforce reduction with $3.0M restructuring charge in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":28168000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223930,"accession_number":"0000950170-24-053215","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outset Medical receives FDA 510(k) clearance for TabloCart with Prefiltration; resumes distribution","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted 510(k) clearance for TabloCart with Prefiltration, an accessory for the Tablo Hemodialysis System.","Outset has resumed distribution and has product available to ship to U.S. customers.","TabloCart features three customizable prefiltration options and a booster pump for variable water conditions.","CEO Leslie Trigg states clearance enhances flexibility for nurses and health systems from ICU to bedside."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243310,"accession_number":"0000950170-24-030779","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Outset Medical appoints Brent Lang to board; Director Szyman resigns for Edwards spinoff CEO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brent D. Lang appointed to the board effective March 12, 2024, filling vacancy left by Catherine Szyman.","Lang is former Chairman & CEO of Vocera Communications, acquired by Stryker for $3 billion in 2022.","Szyman resigned due to pending role as CEO of Edwards Lifesciences' Critical Care spinoff; no disagreement.","Lang will serve on the Audit Committee and be compensated per Outset's non-employee director policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243309,"accession_number":"0000950170-24-017922","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Outset Medical Q4 revenue $30.5M, FY revenue $130.4M; CCO Steve Williamson departs March 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2023 revenue $130.4M (+13% YoY); Q4 revenue $30.5M (-4.7% YoY) due to product revenue decline.","Q4 gross margin 25.3% (non-GAAP 26.7%), up ~900 bps YoY; FY gross margin 22.2% (non-GAAP 23.6%).","Tablo installed base 5,350 consoles exiting 2023; recurring revenue exceeded 50% of total revenue.","2024 guidance reaffirmed: revenue $145-153M (+12-18% YoY); non-GAAP gross margin low-30% range.","CCO Steve Williamson to depart March 1, 2024 to become CEO of another public med device company; no dispute."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":130376000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243308,"accession_number":"0000950170-24-002731","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Outset Medical reports Q4 rev $30.5M, FY2023 $130M (+13%), guides 2024 rev $145-153M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $30.5M; FY2023 revenue $130M, up 13% YoY.","Installed base up 34% YoY to ~5,350 Tablo systems; consumable revenue grew nearly 50% YoY.","Recurring revenue exceeded 50% of total revenue in 2023.","Borrowed $66.5M in Jan 2024; cash position ~$270M.","2024 guidance: revenue $145-153M (12-18% growth); non-GAAP gross margin low-30% for year, mid-30% in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":130376000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243307,"accession_number":"0000950170-24-000306","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Outset Medical borrows $66.5M under SLR term loan facility; outstanding now $200M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $66.5M on Jan 2, 2024 under existing SLR Term Loan Facility.","Total outstanding principal under the facility is now $200.0M after recent borrowings.","No stated use of proceeds; facility was established prior to this draw."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260702,"accession_number":"0000950170-23-069380","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Outset Medical borrows $33.5M under amended SLR term loan; total debt ~$133.5M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Dec 11, 2023, Outset amended its SLR term loan, restructuring the $100M Term B into two tranches: B-1 ($33.5M) and B-2 ($66.5M).","Outset borrowed the full Term B-1 tranche on the amendment date, increasing outstanding principal to ~$133.5M.","The Term A loan of $100M was drawn in Nov 2022; Term B-2 remains available subject to conditions.","No other material terms of the SLR term loan were changed by the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260701,"accession_number":"0000950170-23-060250","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q3 revenue $30.4M (+9% YoY); net loss $46.2M; reiterates FY23 guidance ~$130M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $30.4M, +9% YoY; product rev $23.5M (+8.2%), service rev $6.8M (+13.4%).","GAAP gross margin 23.6% (vs 15.6% YoY); non-GAAP 25.6% (vs 16.4% YoY). Service margin dropped to 6.8% from 37%.","Net loss $46.2M ($0.93/share); non-GAAP net loss $35.3M ($0.71/share).","Cash $197M as of Sept 30; operating expenses $52.6M.","Reiterated 2023 revenue guidance ~$130M, gross margin low-20% for year, mid-20% in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":99869000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260700,"accession_number":"0000950170-23-053108","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical prelim Q3 rev $30.4M (+9% YoY); FY23 guidance cut to ~$130M on FDA letter headwind","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 revenue $30.4M (+9% YoY), gross margin 23.6% (25.6% non-GAAP).","FY23 revenue guidance lowered to ~$130M, citing FDA warning letter impact and cautious capex outlook.","Cash and investments $197M as of Sept. 30, 2023.","CEO notes no deal losses but headwinds expected into Q4; confidence in long-term growth and profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":99869000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277988,"accession_number":"0000950170-23-037134","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q2 revenue $36M (+44% YoY); pauses TabloCart shipment pending 510(k) clearance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $36.0M, up 44% YoY; product revenue $29.3M (+49.5%).","Gross margin improved to 21.4% (22.5% non-GAAP) from 15.1% YoY.","Net loss $44.0M ($0.90/share) vs $43.8M ($0.92) YoY.","Paused shipment of TabloCart with Prefiltration pending FDA 510(k) clearance; plans to file later this month.","Reiterated 2023 revenue guidance $144-150M but expects low end due to pause."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":69507000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277987,"accession_number":"0001193125-23-183869","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA Warning Letter to Outset Medical over Tablo System promotion and TabloCart clearance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Warning Letter dated July 5, 2023 received July 6, 2023, citing two observations: promotional material for CRRT outside Tablo indications, and TabloCart needing 510(k) clearance.","Company believes CRRT issue addressed via labeling/promotional changes; TabloCart launched Q3 2022 with immaterial sales to date.","Warning Letter does not restrict manufacture, shipment, or require withdrawal of Tablo System from U.S. market.","Company to respond within 15 business days; will cooperate with FDA and may submit 510(k) for TabloCart."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296020,"accession_number":"0000950170-23-025692","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Outset Medical shareholders elect three Class III directors at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jim Hinrichs elected with 31,328,771 votes for, 9,103,234 withheld.","Andrea L. Saia elected with 32,411,431 for, 8,020,574 withheld.","Catherine Szyman elected with 30,893,629 for, 9,538,376 withheld.","Advisory vote on 2022 executive compensation approved: 37,566,238 for, 2,837,679 against.","Ratification of KPMG as auditor for FY2023 approved: 42,975,493 for, 29,313 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296019,"accession_number":"0000950170-23-017186","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q1 revenue $33.5M (+9.5% YoY); raises FY2023 revenue and margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $33.5M, up 9.5% YoY; product revenue $27.8M (+8.2%), service revenue $5.7M (+16.4%).","Gross margin 19.2% (20.3% non-GAAP), up from 14.5% a year ago; product margin 25.1% vs 10.0%.","Net loss ($44.0M) or ($0.90) per share; non-GAAP net loss ($35.4M) or ($0.72) per share.","FY2023 revenue guidance raised to $144-$150M (prior $140-$150M); gross margin guidance raised to low-20% (from ~20%).","Added over 30 new hospital sites in Q1, largest quarterly new site growth since 2021; cash $252.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":33467000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316553,"accession_number":"0000950170-23-002612","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Outset Medical Q4 revenue $32M (+14% YoY); COO Vazquez retiring Apr 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $32.0M (+14% YoY); full-year revenue $115.4M (+12.4% YoY).","GAAP gross margin 16.5% (17.1% non-GAAP); operating loss $45.1M.","Tablo installed base grew 54% YoY to ~4,000 systems; 800 home units.","FY 2023 guidance reaffirmed: revenue $140-150M, non-GAAP gross margin ~20%.","COO Martin Vazquez retiring Apr 3, 2023; expected 6-month consulting arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":115375000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316552,"accession_number":"0000950170-23-000462","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Outset Medical reports Q4 2022 expected revenue ~$31.5M; guides FY2023 revenue $140-150M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 expected revenue ~$31.5M (+13% QoQ); FY2022 expected revenue ~$115M (+12% YoY).","Installed base of Tablo systems grew 54% YoY to ~4,000; home provider units doubled to ~800.","FY2022 non-GAAP gross margin expected in mid-teens; FY2023 guidance: ~20% full year, mid-20% exit Q4.","2023 revenue guidance $140M-$150M (22-30% growth over 2022 expected revenue)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":115375000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334817,"accession_number":"0000950170-22-023229","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q3 revenue $27.8M (+5.5% YoY); raises 2022 guidance to $111-113M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $27.8M, +5.5% YoY and +10.8% QoQ; gross margin 15.6% vs 11.2% YoY.","Net loss ($40.8M) / ($0.85) per share; non-GAAP EPS ($0.70).","Raises FY2022 revenue guidance to $111M-$113M from $105M-$110M.","Awarded 5-year VA contract for Tablo at 106 VA hospitals and home settings.","Secured up to $300M in debt financing to strengthen balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":83368000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334816,"accession_number":"0000950170-22-022068","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Outset Medical secures up to $300M in debt financing from SLR Capital Partners","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loan facility up to $250M; $100M drawn at closing with $200M committed initially.","Asset-based revolver up to $50M ($25M committed). Interest: SOFR+5.15% (term) and 3.20% (revolver), 2.75% floor.","Maturity November 1, 2027; interest-only payments for at least 48 months, extendable to 54 months.","Proceeds used to repay existing Silicon Valley Bank debt facility, including $0.3M early repayment fee.","Additional $100M available to borrow at closing; further increases subject to revenue milestones and lender approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352232,"accession_number":"0000950170-22-013586","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Outset Medical Q2 revenue $25.1M flat; FDA clears Tablo for home use; FY22 guidance $105-110M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $25.1M flat YoY; net loss ($43.8M) vs ($30.2M); GAAP EPS ($0.92).","FDA cleared 510(k) for Tablo home use; shipments resumed after voluntary hold.","FY 2022 guidance: revenue $105M-$110M (2-7% growth) citing staffing & inflation pressures.","Gross margin improved to 15.1% from 4.2% YoY, but operating expenses rose to $47.5M vs $31.0M.","Cash $295.4M as of June 30; non-GAAP net loss per share ($0.77)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":55607000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369769,"accession_number":"0000950170-22-011557","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Outset Medical halts home Tablo shipments pending FDA 510(k) review; guides Q2 rev at least $25M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Shipment hold on new Tablo Hemodialysis Systems for home use pending FDA 510(k) clearance of post-March 2020 changes.","Q2 2022 revenue expected at least $25M; prior FY2022 guidance suspended until early August update.","No safety issues identified; Tablo continues to sell for chronic and acute care settings.","Already-distributed home devices not removed; current users can continue treatment with providers.","Company expects update on regulatory review process in Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369768,"accession_number":"0000950170-22-011033","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2022-06-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Outset Medical Annual Meeting: two Class II directors elected, say-on-pay approved, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["D. Keith Grossman and Patrick T. Hackett elected Class II directors until 2025 annual meeting.","Grossman received 20,924,703 For, 21,088,277 Withheld; Hackett 32,671,562 For, 9,341,418 Withheld.","Advisory vote on named executive officer compensation approved: 41,405,031 For, 568,452 Against.","Stockholders favored 'every one year' frequency for future say-on-pay votes (41,970,758 votes); Board adopts annual frequency.","Ratification of KPMG as independent auditor for FY2022 approved: 43,670,077 For, 36,180 Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369767,"accession_number":"0000950170-22-007400","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q1 revenue $30.6M (+33% YoY); narrows FY2022 guidance to $144M-$150M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $30.6M (+33.3% YoY); product revenue $25.7M (+40.9%).","GAAP gross margin 14.5% vs 1.3% YoY; non-GAAP gross margin 14.8%.","GAAP net loss ($36.9M) or ($0.78)/share; non-GAAP net loss ($31.9M) or ($0.67)/share.","FY2022 revenue guidance narrowed to $144M-$150M (prior $142M-$150M), 40-46% growth.","Appointed Dale E. Jones to Board; cash $335.6M; record Tablo Home console shipments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":30550000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369766,"accession_number":"0000950170-22-006095","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Outset Medical appoints Dale E. Jones to Board and Compensation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8 directors; Jones appointed as class I director effective April 21, 2022.","Jones is Senior Advisor at Diversified Search Group, former CEO there for over 8 years.","He also serves on boards of Northwestern Mutual, Special Olympics, Chick-fil-A, and Morehouse College.","Appointed to Compensation Committee; determined independent under Nasdaq and SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388901,"accession_number":"0000950170-22-001362","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2022-02-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Outset Medical Q4 revenue $28.2M, FY21 $102.6M (+105%); guides FY22 $142-150M; CEO adds Chair","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $28.2M (+63% YoY); FY21 revenue $102.6M (+105.5% YoY). GAAP EPS ($0.87); non-GAAP EPS ($0.77).","FY21 GAAP net loss $131.9M ($2.89/share); non-GAAP net loss $114.5M ($2.51/share).","Q4 gross margin 11.8% (vs 2.4% YoY); cash and investments $372.8M at Dec 31, 2021.","FY2022 revenue guidance $142M-$150M representing 38%-46% growth over FY2021.","CEO Leslie Trigg appointed Chair of Board; D. Keith Grossman becomes Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":102602000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406830,"accession_number":"0000950170-21-002832","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q3 revenue $26.3M, up 91% YoY; raises 2021 guidance to $99-101M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $26.3M (+91.3% YoY); product revenue $21.8M (+101.9% YoY).","Net loss $30.5M ($0.65 loss per share); non-GAAP net loss $27.6M ($0.59).","Gross margin improved to 11.2% from (37.3%) a year ago; product gross margin turned positive at 5.9%.","FY2021 revenue guidance raised to $99-101M from prior $97-100M.","Received favorable TPNIES decision for Tablo; cash balance $406.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":74450000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":85915356.13667426,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-03T23:59:59+00:00|406830"}